Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00338091
Status:
TERMINATED
Last Update Posted:
2006-06-20
First Post:
2006-06-16
Brief Title:
Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency
Sponsor:
Southern Medical University China
Organization:
Southern Medical University China
Study Overview
Official Title:
None
Status:
TERMINATED
Status Verified Date:
2002-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary goal of the trial was to evaluate whether the optimal antiproteinuric doses of benazepril an ACE inhibitor or losartan an ARB as compared with their conventional doses can safely improve the long-term renal outcome in nondiabetic patients with proteinuria and chronic renal insufficiency The second aim was to compare the long-term renal protection between benazepril and losartan at similar clinical setting
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None